HemaXis Funding: How Much Did They Raise & Key Investors

How Much Did HemaXis Raise?
Funding & Key Investors

HemaXis, a company focused on innovative micro blood sampling solutions, has secured $2.5M in total capital. The most recent financing round, a Series A, brought in $2.5M on May 3, 2017, signaling a significant strategic investment to further its mission of simplifying blood collection. This enterprise-level funding underscores the growing interest in advanced health monitoring technologies.

The company's approach leverages advanced microfluidics to provide accurate, controlled samples of whole blood, plasma, and serum, aiming to reduce costs and enhance patient comfort in diagnostic processes.

What is HemaXis?

HemaXis

Manufacturing

Medical Devices & Equipment

HemaXis specializes in developing and commercializing innovative micro blood sampling solutions designed to streamline the process of blood collection. Utilizing cutting-edge microfluidics technology, the company's platform enables the precise extraction of small blood volumes, suitable for a range of applications including therapeutic drug monitoring and serology testing for diseases like COVID-19. HemaXis targets a diverse clientele, encompassing clinical laboratories and pharmaceutical firms, with the goal of revolutionizing traditional blood sampling methods by improving accuracy, efficiency, and user experience. Their product suite, featuring devices like the HemaXis DB Whole Blood Collection and HemaXis DX Plasma/Serum Collection, represents a significant advancement in non-invasive health diagnostics.

How much funding has HemaXis raised?

HemaXis has raised a total of $2.5M across 1 funding round:

2017

Series A

$2.5M

Series A (2017): $2.5M, investors not publicly disclosed

What's next for HemaXis?

The substantial enterprise-level backing HemaXis has received, particularly the Series A financing, positions the company for significant scaling and market penetration. This strategic investment is likely to fuel further research and development into their microfluidics technology, expand manufacturing capabilities, and broaden their commercial reach into new geographical markets and application areas. With a focus on simplifying blood collection and reducing associated costs, HemaXis is poised to capture a larger share of the diagnostic and health monitoring sectors, potentially disrupting established players with its more efficient and patient-friendly solutions. Future growth may involve strategic partnerships with larger healthcare providers or diagnostic companies.

See full HemaXis company page

See More Financial Insights